Entering text into the input field will update the search result below

New formulation of Alexion's Ultomiris Ok'd in Europe for rare blood disease and kidney disorder

Nov. 20, 2020 6:00 AM ETAlexion Pharmaceuticals, Inc. (ALXN) StockBy: Meghavi Singh, SA News Editor1 Comment
  • The European Commission has granted marketing authorization to Alexion Pharmaceuticals' (NASDAQ:ALXN) Ultomiris (ravulizumab-cwvz) 100 mg/mL intravenous formulation for the treatment of adults with paroxysmal nocturnal hemoglobinuria (PNH), a rare blood disease in which the immune system destroys red blood cells and atypical hemolytic uremic syndrome

Recommended For You

Related Stocks

SymbolLast Price% Chg
ALXN--
Alexion Pharmaceuticals, Inc.